You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -1,602.9% | -305.7% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -11.1 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 184.2 | 35.3 |
| Price / Book value | 6.5 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 7.9% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2015-04-30 | n/a | -3.87 | -8.12p | -11.6 | 0.0 | n/a | n/a | 0.0% |
| 2016-04-30 | 0.36 | -5.43 | -8.69p | -7.8 | 0.0 | n/a | n/a | 0.0% |
| 2017-04-30 | 0.50 | -7.41 | -8.95p | -5.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-04-30 | 0.63 | -8.93 | -7.91p | -6.0 | 0.0 | n/a | n/a | 0.0% |
| 2019-04-30 | 0.68 | -10.87 | -6.56p | -11.6 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-04-30 | 1.51 | -12.58 | -6.64p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2021-04-30 | 3.52 | -10.77 | -5.54p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2022-04-30 | 0.00 | 0.00 | 0.00p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| Angle upbeat on research into Parsortix with melanoma patients Sharecast News | 11 Feb |
|---|---|
| Angle upbeat on patent grant for prostate cancer blood assessment Sharecast News | 04 Oct |
| Angle initiates main phase of ovarian cancer clinical study Sharecast News | 29 Aug |
| Issue of Equity | 03-Feb-20 09:12 |
|---|---|
| Interim Results | 30-Jan-20 07:06 |
| Change of accounting reference date | 30-Jan-20 07:04 |
| Successful face-to-face meeting with FDA | 22-Jan-20 07:04 |
| Notice of Results | 08-Jan-20 12:34 |